Drugs / Endostatins
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01192230 | Jun 2009 → Dec 2011 | non-small cell lung carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02630264 | Jun 2013 → Jun 2016 | head and neck neoplasm | Guangzhou Double Bioproducts Co., Ltd | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02636231 Comparator | Nov 2015 → Mar 2020 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Endostatins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01192230 ↗ |
| Action | Inhibit | “which inhibits vascular endothelial cell proliferation and tumor angiogenesis” NCT02630264 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human endostatin” PMID 22496834 ↗ Apr 2012 |
| Route | Other | “Patients were treated with escalating doses from 1 x 10(10) VP to 1 x 10(12) VP of E10A intratumorally on days 1 and 8.” PMID 17426445 ↗ Feb 2007 |